Vancomycin: A review of population pharmacokinetic analyses

Clinical Pharmacokinetics

Volumn 51, Issue 1, 2012, Pages 1-13

  Marsot, Amélie ^a   Boulamery, Audrey ^a   Bruguerolle, Bernard ^a   Simon, Nicolas ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Antibacterials; Pharmacokinetic modelling; Population pharmacokinetics; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN;

BODY WEIGHT; CREATININE CLEARANCE; DRUG DISTRIBUTION; DRUG SYNTHESIS; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY;

AGE FACTORS; ANTI-BACTERIAL AGENTS; BODY WEIGHT; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; VANCOMYCIN;

EID: 83455171788     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11596390-000000000-00000     Document Type: Review

References (42)

1. Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42: S5-12 (Pubitemid 41832060)
2. De Hoog M, Mouton JW, Van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 2005; 10: 185-94 (Pubitemid 40215545)
3. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986; 11: 257-82 (Pubitemid 16050520)
4. Oudin C, Vialet R, Boulamery A, et al. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed 2011; 96: F365-70
5. Marques-Minana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates: a new proposal of initial dosage guideline. Br J Clin Pharmacol 2010; 70: 713-20
6. Lo YL, van Hasselt JGC, Heng SC, et al. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother 2010; 54: 2626-32
7. Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63: 75-84 (Pubitemid 44902880)
8. Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of abekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004; 48: 1159-67 (Pubitemid 38405469)
9. Capparelli EV, Lane JR, Romanowski GL, et al. The influence of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001; 41: 927-34 (Pubitemid 32786565)
10. Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in paediatric patients. Ther Drug Monit 2000; 22: 522-31
11. Lamarre P, Lebel D, Ducharme MP. Population pharmacokinetic model for vancomycin in paediatric patients and its predictive value in a nä ve population. Antimicrob Agents Chemother 2000; 44: 278-82 (Pubitemid 30060719)
12. De Hoog M, Schoemaker RC, Mouton JW, et al. Vancomycin population pharmacokinetics. Clin Pharmacol Ther 2000; 67: 360-7
13. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 81: 221-7
14. Yasuhara M, Iga T, Zenda H, et al. Population pharmacokineics of vancomycin in Japanese paediatric patients. Ther Drug Monit 1998; 20: 612-8 (Pubitemid 28544288)
15. Silva R, Reis E, Bispo MA, et al. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol 1998; 50: 1255-60 (Pubitemid 28546602)
16. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169-75 (Pubitemid 24274183)
17. Asbury WH, Darsey EH, Rose WB, et al. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993; 27: 490-6 (Pubitemid 23123902)
18. Schaible DH, Rocci ML, Alpert GA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis 1986; 5: 304-8 (Pubitemid 16115896)
19. Revilla N, Martin-Suarez A, Perez MP, et al. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/ pharmacodynamic simulation. Br J Clin Pharmacol 2010; 70: 201-12
20. Sanchez JL, Dominguez AR, Lane JR, et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther 2010; 48: 525-33
21. Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother 2010; 54: 778-82
22. Dolton M, Xu H, Cheong E, et al. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns 2010; 36: 469-76
23. Yamamoto M, Kuzuya T, Baba H, et al. Population pharmacokinetic analysis of vancomycin in patients with Gram-positive infections and the influence of infectious disease type. J Clin Phar Ther 2009; 34: 473-83
24. Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006; 31: 447-54 (Pubitemid 44337293)
25. Staatz CE, Byrne C, Thomson AH. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol 2005; 61: 164-74
26. Buelga DS, Fernandez de Gatta M, Herrera EV, et al. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother 2005; 49: 4934-41 (Pubitemid 41778903)
27. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005; 60: 265-75 (Pubitemid 41224134)
28. Yasuhara M, Iga T, Zenda H, et al. Population pharmacokineics of vancomycin in Japanese adult patients. Ther Drug Monit 1998; 20: 139-48 (Pubitemid 28163195)
29. Kildoo CW, Lin LM, Gabriel MH, et al. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1989; 14: 77-83 (Pubitemid 20069565)
30. Ohnishi A, Yano Y, Ishibashi T, et al. Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients. Drug Metab Pharmacokinet 2005; 20: 415-22
31. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990; 19: 280-318
32. Shaffer SG, Bradt SK, MeadeVM, et al. Extracellular fluid volume changes in very lowbirth weight infants during first 2 postnatal months. J Pediatr 1987; 111: 124-8 (Pubitemid 17092661)
33. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 122-6 (Pubitemid 27161259)
34. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32 (Pubitemid 351738156)
35. Guignard JP, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics 1999; 103: e49
36. Fernandez deGattaMM,Santos Buelga D, Sanchez-NavarroA, et al. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 2009; 48: 1-8
37. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in patient population: effect of age, gender and body weight. Ther Drug Monit 1994; 16: 513-8 (Pubitemid 24296745)
38. Culter NR, Naravag PK, Lesko JL, et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984; 36: 803-10
39. Vance-Bryan K, Rostchafer JC, Gilliard SS, et al. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus elderly hospitalized patient. J Antimicrob Chemother 1994; 33: 811-21 (Pubitemid 24149817)
40. Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 2001; 13: 461-72 (Pubitemid 33001110)
41. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988; 43: 565-70
42. Sokol PP. Mechanism of vancomycin transport in the kidney: studies in rabbit renal brush border and basolateral membrane vesicles. J Pharmacol Exp Ther 1991; 259: 1283-7